ClinicalTrials.gg
Active, not recruitingNCT06744920RELIEVEUpdated Sep 28, 2026

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

A Phase 3 interventional study of Remibrutinib (Blinded) and Placebo in Generalized Myasthenia Gravis, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 120 sites in 20 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Updated Sep 28, 2026Now Active, not recruitingFirst site in Netherlands+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 144 studies in Myasthenia Gravis with a site in United States — 53 open to participants now, 73 under way, 25 of them phase 3. Myasthenia Gravis · United States.

Planned enrollment
14th of 108
180 · median 56
Started
2025
with 12 others
Phase 3
45 of 144
9 open now
Primary completion
2028-02
later than 43 of 72 live
Registered
117th of 144
by date
Lead sponsor
3 of 144
Novartis Pharmaceuticals

Among the 144 studies in Myasthenia Gravis with a site in United States, this one is the 14th largest by planned enrollment of the 108 interventional ones that give a count, is one of 13 that started in 2025, is one of 45 in phase 3, reaches primary completion later than 43 of the 72 other live ones, and was the 117th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

53 of the 144 studies in Myasthenia Gravis with a site in United States are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 144 studies in Myasthenia Gravis with a site in United States, or all of them as a file.
02

Study summary

A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care (SOC) treatment.

Read the detailed description

This study is a randomized, double-blind, placebo-controlled, multicenter, Phase III study, to evaluate the efficacy, safety and tolerability of remibrutinib in gMG patients who are on stable SOC treatment. Approximately 180 eligible participants will be randomized in a ratio of 1:1, to receive either remibrutinib or matching placebo.

The study consists of a Core Part (6-months double-blind treatment) and an Extension Part (up to 60-month open-label treatment).

03

Conditions studied

  • Generalized Myasthenia Gravis

Browse trials for

Keywords

  • Myasthenia Gravis
  • gMG
  • Generalized Myasthenia Gravis
  • LOU064
  • Remibrutinib
  • placebo-controlled
  • double-blind
  • phase III
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients with gMG (age 18-85 years)
  • Confirmed diagnosis of Myasthenia Gravis Foundation of America (MGFA) Class II-IV gMG at screening and likely not in need of a respirator for the duration of the study, as judged by the Investigator
  • Documented evidence of positive serologic testing for AChR+ antibody or MuSK+ antibody at screening, OR seronegative for both AChR and MuSK antibodies at screening
  • Baseline MG-ADL score ≥ 6 with ≥ 50% of the total score due to non ocular symptoms
  • Participants who have been receiving a standard-of-care treatment as specified in the protocol
  • Able to safely swallow the study medication according to investigator clinical judgement based on a bedside swallowing test or another formal swallowing test in line with local practice, both at Screening and Baseline

Exclusion criteria

Exclusion Criteria:

  • Prior to baseline have been treated with intravenous immunoglobulins or plasma exchange (IVIg/PLEX) in the past month, with rituximab in the past 6 months, eculizumab in the past 2 months, ravulizumab or other complement inhibitors in the past 3 months, efgartigimod or other anti-FcRn therapies in the past 3 months, or had a thymectomy in the past 6 months or a planned thymectomy during the trial period
  • Women of child bearing potential, defined as all women physiologically capable of becoming pregnant, from menarche until becoming , unless they are using highly effective methods of during dosing and for 1 week after stopping of study treatment

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Remibrutinib arm

    Core Part: Remibrutinib tablet taken orally \[Extension Part: Open-label remibrutinib tablet taken orally\]

    Drug: Remibrutinib (Blinded) · Drug: Remibrutinib (Open Label)

  • Placebo comparator
    Placebo arm

    Core Part: Placebo tablet taken orally \[Extension Part: Open-label remibrutinib tablet taken orally\]

    Other: Placebo · Drug: Remibrutinib (Open Label)

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline to Month 6 in Myasthenia Gravis Activity of Daily Living (MG-ADL) total score

    The MG-ADL is a categorical scale that assesses MG symptoms and their effects on daily activities. MG-ADL is composed of items related to patient's assessment of functional disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. Each item is assessed on a 4-points scale where a score 0 represents normal function and a score 3 represents loss of ability to perform that function (total score 0 to 24).

    Time frame: Baseline to Month 6

Secondary outcomes

  1. Change from baseline to Month 6 in Quantitative Myasthenia Gravis (QMG) total score

    The Quantitative Myasthenia Gravis (QMG) Score is a 13-item direct physician assessment scoring system that quantifies disease severity, based on impairments of body functions and structures. The total QMG score ranges from 0 to 39, where higher scores indicated greater disease severity. The QMG score is composed of the following items: ocular (2 items), facial (1 item), bulbar (2 items), gross motor (6 items), axial (1 item) and respiratory (1 item).

    Time frame: Baseline to Month 6

  2. Proportion of participants with ≥ 5 points reduction from baseline to Month 6 of QMG total score without rescue medication and/or strongly confounding prohibited medication

    The Quantitative Myasthenia Gravis (QMG) Score is a 13-item direct physician assessment scoring system that quantifies disease severity, based on impairments of body functions and structures. The total QMG score ranges from 0 to 39, where higher scores indicated greater disease severity. The QMG score is composed of the following items: ocular (2 items), facial (1 item), bulbar (2 items), gross motor (6 items), axial (1 item) and respiratory (1 item).

    Time frame: Baseline to Month 6

  3. Proportion of participants with ≥ 3 points reduction from baseline to Month 6 of Myasthenia Gravis Activity of Daily Living (MG-ADL) scale total score without rescue medication and/or strongly confounding prohibited medication

    The MG-ADL is a categorical scale that assesses MG symptoms and their effects on daily activities. MG-ADL is composed of items related to patient's assessment of functional disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. Each item is assessed on a 4-points scale where a score 0 represents normal function and a score 3 represents loss of ability to perform that function (total score 0 to 24).

    Time frame: Baseline to Month 6

  4. Proportion of participants achieving Minimal Symptom Expression (MSE) at Month 6, defined as MG-ADL score of 0 or 1 at Month 6 without rescue therapy and/or strongly confounding prohibited medication

    The MG-ADL is a categorical scale that assesses MG symptoms and their effects on daily activities. MG-ADL is composed of items related to patient's assessment of functional disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. Each item is assessed on a 4-points scale where a score 0 represents normal function and a score 3 represents loss of ability to perform that function (total score 0 to 24).

    Time frame: Month 6

  5. Change from baseline to Month 6 in Myasthenia Gravis Composite score (MGC) total score

    The MGC is a 10-item instrument that measures the symptoms and signs of MG based on physician examination and patient history. Items relate to ptosis, double vision, eye closure, talking, chewing, swallowing, breathing, neck flexion, shoulder abduction, and hip flexion. Each item is scored on an ordinal scale with 4 possible categories and weighted. The total score ranges from 0 to 50, where higher scores indicating more severe impairments.

    Time frame: Baseline to Month 6

  6. Change from baseline to Month 6 in revised Myasthenia Gravis Quality of Life Questionnaire (MG-QOL15r) survey score

    The revised MG-QoL15 is a 15-item health related quality of life questionnaire completed by participants, designed to measure quality of life in gMG. Items on the MG-QoL15 relate to physical, social, and psychological components and are scored from 0 (not at all) to 2 (very much). The cumulative scores range from 0 to 30, with higher scores representing worse quality of life and dissatisfaction with MG-related dysfunction.

    Time frame: Baseline to Month 6

  7. Incidence of adverse events

    Incidence of adverse events including changes in clinical laboratory values, vital signs, electrocardiograms and suicidality results qualifying and reported as AEs.

    Time frame: Baseline to Month 6

  8. Proportion of time during which participants showed a reduction of ≥ 2 points in MG-ADL total score, that was maintained up to Month 6

    The MG-ADL is a categorical scale that assesses MG symptoms and their effects on daily activities. MG-ADL is composed of items related to patient's assessment of functional disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. Each item is assessed on a 4-points scale where a score 0 represents normal function and a score 3 represents loss of ability to perform that function (total score 0 to 24).

    Time frame: Baseline to Month 6

  9. Proportion of early MG-ADL responders during treatment (early responders with first MG-ADL improvement from baseline of ≥ 2 points occurring by week 4)

    The MG-ADL is a categorical scale that assesses MG symptoms and their effects on daily activities. MG-ADL is composed of items related to patient's assessment of functional disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. Each item is assessed on a 4-points scale where a score 0 represents normal function and a score 3 represents loss of ability to perform that function (total score 0 to 24). Participants with a first MG-ADL improvement from baseline of ≥ 2 points occurring by week 4 are considered early responders.

    Time frame: Baseline to week 4

  10. Change from baseline to Month 6 in EuroQol-5 Dimensions-5 Level (EQ-5D-5L)

    The EQ-5D-5L is a widely used questionnaire designed to assess health status in adults. The measure is divided into two distinct sections, the descriptive system and the EQ visual analogue scale (EQ VAS). The first section includes one item addressing each of five dimensions (mobility, self-care, usual activity, pain/discomfort, and anxiety/depression). Participants rate each of these items from 1 of the 5 levels: no problems, slight problems, moderate problems, severe problems, or unable to/extreme. A composite health state is then defined by combining the levels for each dimension into a 5-digit number. The second section includes the EQ visual analogue scale (EQ VAS) that measures self-rated (global) health status utilizing a vertically oriented visual analogue scale where 100 represents the "best imaginable health state" and 0 represents the "worst imaginable health state." Respondents are asked to rate their current health by placing a mark along this continuum.

    Time frame: Baseline to Month 6

  11. Proportion of participants achieving a reduction from baseline of ≥ 3 points in MGC total score at Month 6

    The MGC is a 10-item instrument that measures the symptoms and signs of MG based on physician examination and patient history. Items relate to ptosis, double vision, eye closure, talking, chewing, swallowing, breathing, neck flexion, shoulder abduction, and hip flexion. Each item is scored on an ordinal scale with 4 possible categories and weighted. The total score ranges from 0 to 50, where higher scores indicating more severe impairments.

    Time frame: Baseline to Month 6

  12. Change from baseline in MG-ADL total score

    The MG-ADL is a categorical scale that assesses MG symptoms and their effects on daily activities. MG-ADL is composed of items related to patient's assessment of functional disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. Each item is assessed on a 4-points scale where a score 0 represents normal function and a score 3 represents loss of ability to perform that function (total score 0 to 24).

    Time frame: Baseline to Month 66

  13. Change from baseline in QMG total score

    The Quantitative Myasthenia Gravis (QMG) Score is a 13-item direct physician assessment scoring system that quantifies disease severity, based on impairments of body functions and structures. The total QMG score ranges from 0 to 39, where higher scores indicated greater disease severity. The QMG score is composed of the following items: ocular (2 items), facial (1 item), bulbar (2 items), gross motor (6 items), axial (1 item) and respiratory (1 item).

    Time frame: Baseline to Month 66

  14. Change from baseline in MGC total score

    The MGC is a 10-item instrument that measures the symptoms and signs of MG based on physician examination and patient history. Items relate to ptosis, double vision, eye closure, talking, chewing, swallowing, breathing, neck flexion, shoulder abduction, and hip flexion. Each item is scored on an ordinal scale with 4 possible categories and weighted. The total score ranges from 0 to 50, where higher scores indicating more severe impairments.

    Time frame: Baseline to Month 66

  15. Proportion of participants achieving a reduction from core part in oral corticosteroids (OCS) dose till the end of extension part

    Participants receiving oral corticosteroids are required to be on a stable dose for at least 4 weeks prior to baseline. The dose can be reduced or discontinued during the open label extension period at investigator discretion. Oral corticosteroids use will be recorded.

    Time frame: Baseline to month 66

  16. Incidence of adverse events

    Incidence of adverse events including changes in clinical laboratory values, vital signs, electrocardiograms and suicidality results qualifying and reported as AEs.

    Time frame: Month 7 to month 66

07

Study locations

120 sites
  • Neuromuscular Research Center
    Phoenix, Arizona 85013, United States
  • Honor Health Research Institute
    Scottsdale, Arizona 85258, United States
  • Fullerton Neuro and Headache Ctr
    Fullerton, California 92835, United States
  • University Of Southern California
    Los Angeles, California 90033, United States
  • California Pacific Medical Center
    Sacramento, California 94115, United States
  • Medstar Washington Hospital Center
    Washington D.C., District of Columbia 20010-2975, United States
  • SFM Clinical Research LLC
    Boca Raton, Florida 33487, United States
  • Homestead Assoc In Research Inc
    Homestead, Florida 33033, United States
  • Neurology Associates PA
    Maitland, Florida 32751, United States
  • AdventHealth
    Orlando, Florida 32804, United States
  • Neurological Services of Orlando PA
    Orlando, Florida 32806, United States
  • University of Chicago Medical Centr
    Chicago, Illinois 60637, United States
  • Mid Atlantic Epilepsy and Sleep Ctr
    Bethesda, Maryland 20817-1807, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Michigan State University-Department of Neurology
    East Lansing, Michigan 48824, United States
  • Dent Neurological Institute
    Buffalo, New York 14209, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
  • UT Health Science Center
    Houston, Texas 77030, United States
  • University of Texas Health Science Center at San Antonio
    San Antonio, Texas 78229-3900, United States
  • University of WA Division of Cardio
    Seattle, Washington 98195, United States
  • Center for Neurological Disorders G
    Greenfield, Wisconsin 53228-1321, United States
  • Novartis Investigative Site
    Rosario, Santa Fe Province 2000, Argentina
  • Novartis Investigative Site
    Buenos Aires, C1012AAR, Argentina
  • Novartis Investigative Site
    Caba, C1055AAF, Argentina
  • Novartis Investigative Site
    Capital Federal, C1023AAB, Argentina
  • Novartis Investigative Site
    San Miguel de Tucumán, T4000AXL, Argentina
  • Novartis Investigative Site
    Fitzroy, Victoria 3065, Australia
  • Novartis Investigative Site
    Salvador, Estado de Bahia 40050-410, Brazil
  • Novartis Investigative Site
    Brasília, Federal District 70200-730, Brazil
  • Novartis Investigative Site
    Caxias do Sul, Rio Grande do Sul 95070-560, Brazil
  • Novartis Investigative Site
    Porto Alegre, Rio Grande do Sul 90480-110, Brazil
  • Novartis Investigative Site
    São Paulo, 05403-000, Brazil
  • Novartis Investigative Site
    London, Ontario N6A 5W9, Canada
  • Novartis Investigative Site
    Ottawa, Ontario K1H 8L6, Canada
  • Novartis Investigative Site
    Québec, Quebec G1J 1Z4, Canada
  • Novartis Investigative Site
    Hefei, Anhui 230001, China
  • Novartis Investigative Site
    Guangzhou, Guangdong 510080, China
  • Novartis Investigative Site
    Shijiazhuang, Hebei 050030, China
  • Novartis Investigative Site
    Zhengzhou, Henan 450003, China
  • Novartis Investigative Site
    Wuhan, Hubei 430030, China
  • Novartis Investigative Site
    Wuxi, Jiangsu 214023, China
  • Novartis Investigative Site
    Changchun, Jilin 130021, China
  • Novartis Investigative Site
    Beijing, 100034, China
  • Novartis Investigative Site
    Beijing, 100730, China
  • Novartis Investigative Site
    Qingdao, 266000, China
  • Novartis Investigative Site
    Shanghai, 200040, China
  • Novartis Investigative Site
    Shanghai, 200080, China
  • Novartis Investigative Site
    Bordeaux, 33076, France
  • Novartis Investigative Site
    Nice, 06000, France
  • Novartis Investigative Site
    Paris, 75013, France
  • Novartis Investigative Site
    Paris, 75940, France
  • Novartis Investigative Site
    Strasbourg, 67081, France
  • Novartis Investigative Site
    Toulouse, 31059, France
  • Novartis Investigative Site
    Kutaisi, 4600, Georgia
  • Novartis Investigative Site
    Tbilisi, 0114, Georgia
  • Novartis Investigative Site
    Tbilisi, 0144, Georgia
  • Novartis Investigative Site
    Frankfurt am Main, Hesse 60590, Germany
  • Novartis Investigative Site
    Gummersbach, 51643, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Münster, 48149, Germany
  • Novartis Investigative Site
    Gurugram, Haryana 122011, India
  • Novartis Investigative Site
    Mangalore, Karnataka 575002, India
  • Novartis Investigative Site
    Nashik, Maharashtra 422005, India
  • Novartis Investigative Site
    New Delhi, National Capital Territory of Delhi 110029, India
  • Novartis Investigative Site
    Ludhiana, Punjab 141001, India
  • Novartis Investigative Site
    Vellore, Tamil Nadu 632004, India
  • Novartis Investigative Site
    Hyderabad, Telangana 500082, India
  • Novartis Investigative Site
    Lucknow, Uttar Pradesh 226007, India
  • Novartis Investigative Site
    Bergamo, BG 24127, Italy
  • Novartis Investigative Site
    Orbassano, TO 10043, Italy
  • Novartis Investigative Site
    Sapporo, Hokkaido 0608543, Japan
  • Novartis Investigative Site
    Sapporo, Hokkaido 0630005, Japan
  • Novartis Investigative Site
    Nishinomiya, Hyōgo 6638501, Japan
  • Novartis Investigative Site
    Hanamaki, Iwate 0250082, Japan
  • Novartis Investigative Site
    Sendai, Miyagi 9838520, Japan
  • Novartis Investigative Site
    Suita, Osaka 5650871, Japan
  • Novartis Investigative Site
    Higashi-Matsuyama, Saitama 3550005, Japan
  • Novartis Investigative Site
    Koshigaya, Saitama 3438555, Japan
  • Novartis Investigative Site
    Shinjuku Ku, Tokyo 1600023, Japan
  • Novartis Investigative Site
    Shinjuku-ku, Tokyo 1608582, Japan
  • Novartis Investigative Site
    Chiba, 2608677, Japan
  • Novartis Investigative Site
    Fukuoka, 8128582, Japan
  • Novartis Investigative Site
    Fukushima, 9601295, Japan
  • Novartis Investigative Site
    Hiroshima, 7348551, Japan
  • Novartis Investigative Site
    Amsterdam, North Holland 1105 AZ, Netherlands
  • Novartis Investigative Site
    Lublin, Lublin Voivodeship 20-064, Poland
  • Novartis Investigative Site
    Lublin, Lublin Voivodeship 20-080, Poland
  • Novartis Investigative Site
    Krakow, POL 31-505, Poland
  • Novartis Investigative Site
    Bydgoszcz, 85-065, Poland
  • Novartis Investigative Site
    Katowice, 40-689, Poland
  • Novartis Investigative Site
    Lodz, 93-113, Poland
  • Novartis Investigative Site
    Lublin, 20-410, Poland
  • Novartis Investigative Site
    Lublin, 20-701, Poland
  • Novartis Investigative Site
    Poznan, 61-731, Poland
  • Novartis Investigative Site
    Skorzewo, 60-185, Poland
  • Novartis Investigative Site
    Warsaw, 01-684, Poland
  • Novartis Investigative Site
    Warsaw, 02-172, Poland
  • Novartis Investigative Site
    Brasov, 500283, Romania

Showing the first 100 of 120 sites across 20 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Feb 2028, 36 months after the start.

Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's planned 36 months is above that.

Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2024
First posted
Dec 20, 2024
StartActual
Feb 7, 2025
Primary completionEst.
Feb 25, 2028
CompletionEst.
Feb 26, 2033
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Sep 28, 2026
Sites
7 sites added, 17 sites removed — first site in Netherlands; no longer in Belgium
Show 7 added (2 Japan, 1 United States, 1 Argentina, 1 Brazil, 1 Netherlands, 1 South Korea)
  • University of Texas Health Science Center at San Antonio · San Antonio, United States
  • Novartis Investigative Site · Buenos Aires, Argentina
  • Novartis Investigative Site · São Paulo, Brazil
  • Novartis Investigative Site · Shinjuku-ku, Japan
  • Novartis Investigative Site · Chiba, Japan
  • Novartis Investigative Site · Amsterdam, Netherlands
  • Novartis Investigative Site · Seoul, South Korea
Show 17 removed
  • Univ Cali Irvine ALS Neuromuscular · Orange, United States
  • Univ of Cincinnati Medical Center · Cincinnati, United States
  • Novartis Investigative Site · Kogarah, Australia
  • Novartis Investigative Site · Southport, Australia
  • Novartis Investigative Site · Leuven, Belgium
  • Novartis Investigative Site · Porto Alegre, Brazil
  • Novartis Investigative Site · São Paulo, Brazil
  • Novartis Investigative Site · Edmonton, Canada
  • Novartis Investigative Site · Naples, Italy
  • Novartis Investigative Site · Chiba, Japan
  • Novartis Investigative Site · Bydgoszcz, Poland
  • Novartis Investigative Site · Rzeszów, Poland
  • Novartis Investigative Site · Szczecin, Poland
  • Novartis Investigative Site · Seoul, South Korea
  • Novartis Investigative Site · Santiago Compostela, Spain
  • Novartis Investigative Site · L'Hospitalet de Llobregat, Spain
  • Novartis Investigative Site · London, United Kingdom
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Recruiting→Active, not recruiting
    7 sites added, 17 sites removed — first site in Netherlands; no longer in Belgium
    Show 7 added (2 Japan, 1 United States, 1 Argentina, 1 Brazil, 1 Netherlands, 1 South Korea)
    • University of Texas Health Science Center at San Antonio · San Antonio, United States
    • Novartis Investigative Site · Buenos Aires, Argentina
    • Novartis Investigative Site · São Paulo, Brazil
    • Novartis Investigative Site · Shinjuku-ku, Japan
    • Novartis Investigative Site · Chiba, Japan
    • Novartis Investigative Site · Amsterdam, Netherlands
    • Novartis Investigative Site · Seoul, South Korea
    Show 17 removed
    • Univ Cali Irvine ALS Neuromuscular · Orange, United States
    • Univ of Cincinnati Medical Center · Cincinnati, United States
    • Novartis Investigative Site · Kogarah, Australia
    • Novartis Investigative Site · Southport, Australia
    • Novartis Investigative Site · Leuven, Belgium
    • Novartis Investigative Site · Porto Alegre, Brazil
    • Novartis Investigative Site · São Paulo, Brazil
    • Novartis Investigative Site · Edmonton, Canada
    • Novartis Investigative Site · Naples, Italy
    • Novartis Investigative Site · Chiba, Japan
    • Novartis Investigative Site · Bydgoszcz, Poland
    • Novartis Investigative Site · Rzeszów, Poland
    • Novartis Investigative Site · Szczecin, Poland
    • Novartis Investigative Site · Seoul, South Korea
    • Novartis Investigative Site · Santiago Compostela, Spain
    • Novartis Investigative Site · L'Hospitalet de Llobregat, Spain
    • Novartis Investigative Site · London, United Kingdom
    + 3 other changes: identifiers, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06744920
Responsible party
Sponsor
First posted
Dec 20, 2024
Start date
Feb 7, 2025
Primary completion
Feb 25, 2028 (estimated)
Completion
Feb 26, 2033 (estimated)
Last update
Sep 28, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remibrutinib

Start the discussion